CN Patent

CN101743003A — 用于治疗癌症的chk和parp抑制剂的组合

Assigned to AstraZeneca AB · Expires 2010-06-16 · 16y expired

What this patent protects

描述了一种组合，其包含限制点激酶(CHK)抑制剂或其药学可接受的盐，以及聚(ADP-核糖)聚合酶(PARP)抑制剂或其药学可接受的盐。

USPTO Abstract

描述了一种组合，其包含限制点激酶(CHK)抑制剂或其药学可接受的盐，以及聚(ADP-核糖)聚合酶(PARP)抑制剂或其药学可接受的盐。

Drugs covered by this patent

Patent Metadata

Patent number: CN101743003A
Jurisdiction: CN
Classification: —
Expires: 2010-06-16
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.